As the shutdown began and the lights went out in the ETH labs a new consortium crystalized around the idea of developing a vaccine. With special permission from the ETH Executive Board to continue wet-lab research the project quickly got moving and testing of the first vaccine candidates is now underway.
Globally, there are more than 100 covid-19 vaccines in the pipeline. It is only a matter of time until this enormous effort begins bearing fruit. Our vaccine will not be the fastest through the development pipeline, but it will have one important advantage. In contrast to many of the first wave of vaccines that require sophisticated and expensive biotechnological production facilities, this vaccine is designed to be cheap and easy to produce, to be manufactured directly in low- and middle-income countries. This vaccine has the potential to reach into corners of the world that need it most.